Agilent Technologies Stock: Analyst Estimates & Ratings

Despite underperforming the broader market, analysts remain moderately bullish on Agilent's prospects

Published on Feb. 28, 2026

Got story updates? Submit your updates here. ›

Agilent Technologies, a leading provider of instruments, software, services and consumables for laboratory workflows, has underperformed the broader market over the past year. However, analysts remain moderately bullish on the company's prospects, with a consensus 'Moderate Buy' rating and a mean price target suggesting a 35.5% premium to the current stock price.

Why it matters

Agilent's performance is closely watched as it is a significant player in the healthcare and research tools sector. The company's stock price movements and analyst sentiment can provide insights into the broader trends and challenges facing the industry.

The details

Agilent's stock has declined 7.9% over the past 52 weeks and 7.2% on a year-to-date basis, underperforming the S&P 500 Index's 11.7% gains over the past year. The stock has also lagged behind the sector-focused State Street Health Care Select Sector SPDR ETF's 7.4% gains over the past 52 weeks. The downward pressure on Agilent's stock has been largely due to weak sentiment and profit-taking, despite stable fundamentals and a positive outlook for the long term.

  • Agilent's fiscal year ends in October.
  • For the full fiscal 2026, analysts expect Agilent to deliver an EPS of $5.93, up 6.1% year-over-year.
  • Last month, HSBC initiated coverage on Agilent Technologies with a 'Buy' rating and a $180 price target.

The players

Agilent Technologies, Inc.

A leading provider of instruments, software, services and consumables that support laboratory workflows across life sciences, diagnostics and applied chemical markets worldwide. Agilent is headquartered in Santa Clara, California and has a market cap of $35.8 billion.

State Street Health Care Select Sector SPDR ETF (XLV)

A sector-focused exchange-traded fund that tracks the performance of the healthcare sector in the S&P 500 Index.

HSBC

A global financial services company that recently initiated coverage on Agilent Technologies with a 'Buy' rating and a $180 price target.

Got photos? Submit your photos here. ›

The takeaway

Despite Agilent's recent stock underperformance, the majority of analysts covering the company remain bullish on its prospects, with a consensus 'Moderate Buy' rating and a mean price target suggesting significant upside potential. This suggests that the market may be undervaluing Agilent's fundamentals and long-term growth potential.